Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India
A Phase II/III, Randomized, Comparative Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in India
Sponsor: Pfizer
This PHASE2/PHASE3 trial investigates PLASMODIUM FALCIPARUM MALARIA and is currently completed. Pfizer leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
Sep 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Bambolim, India
- • Dispur Guwahati, India
- • Indore, India
- • Nagpur, India
- • Parel Mumbai, India
- • Rourkela, India
- • Vellore, India